<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298985</url>
  </required_header>
  <id_info>
    <org_study_id>VLJB-14</org_study_id>
    <nct_id>NCT02298985</nct_id>
  </id_info>
  <brief_title>Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients</brief_title>
  <official_title>Curcumin as add-on to Antipsychotic Treatment in Chronic Schizophrenia Patients: A Randomized, Double-Blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beersheva Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tirat Carmel Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beersheva Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is still remained one of the disabling disorders despite progress in treatment&#xD;
      of mental disturbances. Ten to thirty percents of patients have a little or no benefit from&#xD;
      treatment with all kinds of antipsychotics using adequate dosages and duration. Treatment of&#xD;
      these patients has remained a persistent public health problem since medication-resistant&#xD;
      patients are often highly symptomatic. Curcumin is one of the main curcuminoids isolated from&#xD;
      this perennial herb. It possesses a variety of pharmacological activities, including&#xD;
      anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects and crosses&#xD;
      the blood-brain barrier. The purpose of our suggested study is to examine the efficacy of&#xD;
      curcumin as add-on the conventional antipsychotic psychopharmacotherapy in chronic&#xD;
      schizophrenia patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design This is a 24-week, randomized, double-blind, placebo-controlled investigation of&#xD;
      40 chronic schizophrenia patients.&#xD;
&#xD;
      Participants Forty patients will be drawn from the patient population of Be'er Sheva Mental&#xD;
      Health Center. Recruitment period will last over 2 years.&#xD;
&#xD;
      Patients will be required to have a primary diagnosis of chronic schizophrenia as defined in&#xD;
      DSM-IV with predominantly persistent negative signs.&#xD;
&#xD;
      The study will commence only after approval by the local Institutional Ethics Review Board&#xD;
      (&quot;Helsinki Committee&quot;). Only willing subjects and able to provide written informed consent,&#xD;
      after receiving a comprehensive explanation of the study procedures, will be included in the&#xD;
      study. Confidentially will be ensured by means of a number coding system, and all completed&#xD;
      research forms will be stored in secure areas.&#xD;
&#xD;
      Procedure Patients will continue receiving their regular antipsychotic medication. The dose&#xD;
      will be kept constant for at least 3 months prior to entry and throughout the study period.&#xD;
      Curcumin is provided as Curcumin Forte Â® (Solgar Israel SupHerb). Circumin capsules are&#xD;
      supplied as an 1000 mg soft gelatin capsule for three daily oral administration with meals.&#xD;
      At entry patients will receive curcuma capsules (3000 mg/day, three capsules) or placebo in&#xD;
      identical capsules in a randomized, double blind mode for 24 weeks: 20 patients will receive&#xD;
      curcumin, and 20 patients - placebo.&#xD;
&#xD;
      Participants will be assessed at baseline and after 4, 8, 12, 16 and 24 weeks of treatment.&#xD;
      In a case of treatment discontinuation for 24-week of the trial, patients will be followed&#xD;
      until end of study period.&#xD;
&#xD;
      Outcome variables will be evaluated by scoring the severity of symptoms (positive, negative,&#xD;
      and etc.), and side effects. In addition, liver function tests and a blood cell count will be&#xD;
      monitored at baseline and during the study.&#xD;
&#xD;
      For analyzing the results, within-subject pre- and post-treatment responses would be subject&#xD;
      to statistical procedures to evaluate whether curcumin can ameliorate the persistent negative&#xD;
      symptoms in schizophrenia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Symptoms Scale (PANSS)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>baseline and every week 4 up to 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Improvement (CGI-I)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>baseline and every week 4 up to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Severity of Adverse Events (CGI-SAE)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>baseline and every week 4 up to 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale for Schizophrenia (CDSS)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>baseline and every week 4 up to 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Chronic Schizophrenia</condition>
  <arm_group>
    <arm_group_label>curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>curcumin 3 g/day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>curcumin 3 g/day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>3 g/day (3 capsules/day) for 6 months</description>
    <arm_group_label>curcumin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
    <other_name>regular antipsychotic medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 g/day (3 capsules/day) for 6 months</description>
    <arm_group_label>curcumin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>curcumin</other_name>
    <other_name>regular antipsychotic medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years, male or female&#xD;
&#xD;
          -  DSM-IV criteria for schizophrenia.&#xD;
&#xD;
          -  Ability and willingness to sign informed consent for participation in the study&#xD;
&#xD;
          -  SANS (Scale of Negative Symptoms of Schizophrenia ) &gt; 30 points&#xD;
&#xD;
          -  Fixed antipsychotic dosages at least 3 months&#xD;
&#xD;
          -  Steady mental state of patients at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current substance use disorder except nicotine dependence&#xD;
&#xD;
          -  Regular use of NSAID (non-steroidal anti-inflammatory drugs)&#xD;
&#xD;
          -  Cancer history&#xD;
&#xD;
          -  Untreated or severe hypertension&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus Type I or Type II&#xD;
&#xD;
          -  Chronic liver &amp; gallbladder diseases&#xD;
&#xD;
          -  Recent GERD (Gastroesophageal Reflux Disorder)&#xD;
&#xD;
          -  Neurological disorders: epilepsy, stroke&#xD;
&#xD;
          -  Hamilton Depression Scale Hamilton Depression Rating Scale (HAM-D-17 item) &gt; 24 points&#xD;
&#xD;
          -  Patients with a known hypersensitivity to curcumin&#xD;
&#xD;
          -  Pregnant women or a woman who intends to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Lerner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beersheva Mental Health Center</name>
      <address>
        <city>Beersheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tirat Carmel Mental Health Center</name>
      <address>
        <city>Tirat Carmel</city>
        <zip>84170</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beersheva Mental Health Center</investigator_affiliation>
    <investigator_full_name>Vladimir Lerner</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>curcumin; schizophrenia; neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

